We report short- and intermediate-term effects on headaches with intra-arterial injection of lidocaine in the middle meningeal artery in patients with severe headaches associated with subarachnoid hemorrhage.
Methods
We treated seven patients with intra-arterial lidocaine in doses up to 50 mg in each middle meningeal artery via a microcatheter bilaterally (except in one patient). We recorded the maximum intensity of headache (graded by 11-point numeric rating scale) prior to procedure and every day for the next 10 days or discharge, whichever came first. We identified changes in the middle meningeal artery pre- and post-intra-arterial lidocaine administration and quantified from Grade 0 (no change) to Grade 5 (severe narrowing or near occlusion of anterior and posterior dural branches or proximal middle meningeal artery that precludes adequate imaging of distal branches).
Results
We observed improvement in severity of headaches of headache in all seven subarachnoid hemorrhage patients. The resolution of headache was immediate and complete in four patients, unilateral immediate resolution in one patient, and delayed complete resolution in patient. Two patients met the definition of severe headache (defined as 2 or more days with maximum pain scores of 8 or greater or need for 3 or more different analgesics for 2 or more days) post-lidocaine treatment. One of these patients had are lapse in headache with the severity matching pretreatment severity and required a second treatment. On analysis of angiographic data, there was consistent narrowing of middle meningeal arteries after administration of intra-arterial lidocaine and was graded as 5 in 2 arteries, 4 in 10 arteries, and 3 in 2 arteries.
Conclusions
We found that intra-arterial injection of lidocaine can result in consistent amelioration of headache in patients with subarachnoid hemorrhage. The therapeutic benefit may be related to vasoconstriction (reversal of vasodilation) in the middle meningeal arteries after administration of lidocaine.
GorelickPBHierDBCaplanLR, et al.Headache in acute cerebrovascular disease. Neurology1986; 36: 1445–1450.
2.
Dorhout MeesSMBertensDvan der WorpHB, et al.Magnesium and headache after aneurysmal subarachnoid haemorrhage. J Neurol Neurosurg Psychiatry2010; 81: 490–493. 20091013.
3.
SwopeRGloverKGokunY, et al.Evaluation of headache severity after aneurysmal subarachnoid hemorrhage. Interdisciplinary Neurosurgery2014; 1: 119–122.
4.
GlisicEKGardinerLJostiL, et al.Inadequacy of headache management after subarachnoid hemorrhage. Am J Crit Care2016; 25: 136–143.
5.
ViswanathanVLucke-WoldBJonesC, et al.Change in opioid and analgesic use for headaches after aneurysmal subarachnoid hemorrhage over time. Neurochirurgie2021; 67: 427–432. 20210323.
6.
BouchierBDemarquayGDaillerF, et al.Course of headaches and predictive factors associated with analgesia failure following spontaneous subarachnoid hemorrhage: a prospective cohort study. J Neurosurg Anesthesiol2023; 35: 333–337. 20220503.
7.
MoradAHTamargoRJGottschalkA.The longitudinal course of pain and analgesic therapy following aneurysmal subarachnoid hemorrhage: a cohort study. Headache2016; 56: 1617–1625. 20161005.
8.
QureshiAIQureshiMHKhanAA, et al.Effect of intra-arterial injection of lidocaine and methyl-prednisolone into middle meningeal artery on intractable headaches. J Vasc Interv Neurol2014; 7: 69–72.
9.
Mancuso-MarcelloMQureshiAINikolaC, et al.Intra-arterial lidocaine therapy via the middle meningeal artery for migraine headache: theory, current practice and future directions. Interv Neuroradiol2023: 15910199231195470. doi:https://doi.org/10.1177/15910199231195470
10.
Unal-CevikIArslanD. Similarities and differences between migraine and other types of headaches: migraine mimics. Neurology Perspectives2023; 3: 100122.
11.
DreierJPSakowitzOWUnterbergAW, et al.Migrainous aura starting several minutes after the onset of subarachnoid hemorrhage. Neurology2001; 57: 1344–1345.
12.
HankeyGJNelsonMR. Subarachnoid haemorrhage. Br Med J2009; 339: b2874.
13.
SilbersteinSDDodickDWPearlmanS.Defining the pharmacologically intractable headache for clinical trials and clinical practice. Headache2010; 50: 1499–1506. 2010/10/21.
14.
LoderEBurchR.Measuring pain intensity in headache trials: which scale to use?Cephalalgia2012; 32: 179–182. 2012/01/31.
15.
AicherBPeilHPeilB, et al.Pain measurement: visual analogue scale (VAS) and verbal rating scale (VRS) in clinical trials with OTC analgesics in headache. Cephalalgia2012; 32: 185–197. 2012/02/15.
16.
QureshiAISaleemMAJadhavV, et al.Intra-arterial modulation of the trigeminal nerve ganglion in patients with refractory trigeminal neuralgia. J Neuroimaging2018; 28: 79–85. 2017/10/07.
17.
DeToledoJCMinagarALoweMR.Lidocaine-induced seizures in patients with history of epilepsy: effect of antiepileptic drugs. Anesthesiology2002; 97: 737–739. 2002/09/10.
18.
ChuangVPWidrichWC.Complications from intraarterial lidocaine in upper extremity arteriography. AJR Am J Roentgenol1978; 131: 906. 1978/11/01.
19.
PenfieldWMcNaughtonF. Dural headache and innervation of the dura mater. Arch Neurol Psychiatry1940; 44: 43–75.
20.
CavallottiDArticoMDe SantisS, et al.Catecholaminergic innervation of the human dura mater involved in headache. Headache1998; 38: 352–355. 1998/06/19.
21.
WilliamsonDJHillRGShepheardSL, et al.The anti-migraine 5-HT(1B/1D) agonist rizatriptan inhibits neurogenic dural vasodilation in anaesthetized guinea-pigs. Br J Pharmacol2001; 133: 1029–1034. 2001/08/07.
22.
KempWJ3rdTubbsRSCohen-GadolAA.The innervation of the cranial dura mater: neurosurgical case correlates and a review of the literature. World Neurosurg2012; 78: 505–510. 2011/11/29.
23.
AkermanSHollandPRLasalandraMP, et al.Inhibition of trigeminovascular dural nociceptive afferents by Ca(2+)-activated K(+) (MaxiK/BK(Ca)) channel opening. Pain2010; 151: 128–136. 2010/07/27.
24.
McIlvriedLAAlbersKGoldMS.Distribution of artemin and GFRalpha3 labeled nerve fibers in the dura mater of rat: artemin and GFRalpha3 in the dura. Headache2010; 50: 442–450. 2009/10/23.
25.
QureshiAIPfeifferKBabarS, et al.Intra-arterial injection of lidocaine into middle meningeal artery to treat intractable headaches and severe migraine. J Neuroimaging2021; 31: 1126–1134.
26.
BonasiaSSmajdaSCiccioG, et al.Middle meningeal artery: anatomy and variations. AJNR Am J Neuroradiol2020; 41: 1777–1785. 20200903.
27.
LambertGATruongLZagamiAS.Effect of cortical spreading depression on basal and evoked traffic in the trigeminovascular sensory system. Cephalalgia2011; 31: 1439–1451. 20110922.
28.
KorstenHHAckermanEWGroulsRJ, et al.Long-lasting epidural sensory blockade by n-butyl-p-aminobenzoate in the terminally ill intractable cancer pain patient. Anesthesiology1991; 75: 950–960.
29.
CollinsworthKAKalmanSMHarrisonDC. The clinical pharmacology of lidocaine as an antiarrhythymic drug. Circulation1974; 50: 1217–1230.
30.
SchuelerMNeuhuberWLDe ColR, et al. Innervation of rat and human dura mater and pericranial tissues in the parieto-temporal region by meningeal afferents. Headache2014; 54: 996–1009. 20140506.
31.
BursteinRYamamuraHMalickA, et al.Chemical stimulation of the intracranial dura induces enhanced responses to facial stimulation in brain stem trigeminal neurons. J Neurophysiol1998; 79: 964–982.
32.
OlesenJBursteinRAshinaM, et al.Origin of pain in migraine: evidence for peripheral sensitisation. Lancet Neurol2009; 8: 679–690.
MohammadY. Therapeutic use of the newly described “Artery of Qureshi”. J Vasc Interv Neurol2018; 10: 65. 2018/06/21.
35.
LobanovaIQureshiAI.An intra-arterial therapeutic route to the trigeminal nerve ganglion in patients with refractory trigeminal neuralgia. J Neuroimaging2018; 28: 549. 2018/08/08.
36.
KhanSAminFMChristensenCE, et al.Meningeal contribution to migraine pain: a magnetic resonance angiography study. Brain2019; 142: 93–102.
37.
AsgharMSHansenAEAminFM, et al.Evidence for a vascular factor in migraine. Ann Neurol2011; 69: 635–645. 20110317.
38.
AminFMHougaardASchytzHW, et al.Investigation of the pathophysiological mechanisms of migraine attacks induced by pituitary adenylate cyclase-activating polypeptide-38. Brain2014; 137: 779–794. 20140205.
39.
GoadsbyPJKnightYEHoskinKL, et al.Stimulation of an intracranial trigeminally-innervated structure selectively increases cerebral blood flow. Brain Res1997; 751: 247–252.
40.
MacfarlaneRMoskowitzMA. The innervation of pial blood vessels and their role in cerebrovascular regulation. In: CaplanLR (eds) Brain ischemia: basic concepts and clinical relevance. London: Springer London, 1995, pp.247–259.
41.
ShahKAWhiteTGPowellK, et al.Trigeminal nerve stimulation improves cerebral macrocirculation and microcirculation after subarachnoid hemorrhage: an exploratory study. Neurosurgery2022; 90: 485–494.
42.
EdvinssonJCAViganòAAlekseevaA, et al.The fifth cranial nerve in headaches. J Headache Pain2020; 21: 65. 20200605.
43.
MaybergMRZervasNTMoskowitzMA. Trigeminal projections to supratentorial pial and dural blood vessels in cats demonstrated by horseradish peroxidase histochemistry. J Comp Neurol1984; 223: 46–56.
44.
TangYSheDLiP, et al.Cortical spreading depression aggravates early brain injury in a mouse model of subarachnoid hemorrhage. J Biophotonics2021; 14: e202000379. 20210103.
45.
SugimotoKChungDY. Spreading depolarizations and subarachnoid hemorrhage. Neurotherapeutics2020; 17: 497–510.
46.
BerhoumaMEkerOFDaillerF, et al.Cortical spreading depolarizations in aneurysmal subarachnoid hemorrhage: an overview of current knowledge and future perspectives. Adv Tech Stand Neurosurg2022; 45: 229–244.
47.
BusijaDWBariFDomokiF, et al.Mechanisms involved in the cerebrovascular dilator effects of cortical spreading depression. Prog Neurobiol2008; 86: 379–395. 20080912.
48.
BolayHReuterUDunnAK, et al.Intrinsic brain activity triggers trigeminal meningeal afferents in a migraine model. Nat Med2002; 8: 136–142.
49.
SmithCRFoxWCRobinsonCP, et al.Pterygopalatine fossa blockade as novel, narcotic-sparing treatment for headache in patients with spontaneous subarachnoid hemorrhage. Neurocrit Care2021; 35: 241–248. 20210105.
50.
NewtonDJMcLeodGAKhanF, et al.Mechanisms influencing the vasoactive effects of lidocaine in human skin. Anaesthesia2007; 62: 146–150.
51.
AustenWGMoranJM. Cardiac and peripheral vascular effects of lidocaine and procainamide. Am J Cardiol1965; 16: 701–707.
52.
MajureDTHallauxMYeghiazariansY, et al.Topical nitroglycerin and lidocaine locally vasodilate the radial artery without affecting systemic blood pressure: a dose-finding phase I study. J Crit Care2012; 27: 532.e539–532.e513.
53.
JernbeckJSamuelsonUE. Effects of lidocaine and calcitonin gene-related peptide (CGRP) on isolated human radial arteries. J Reconstr Microsurg1993; 9: 361–365.
54.
WadströmJGerdinB. Modulatory effects of topically administered lidocaine and pentobarbital on traumatic vasospasm in the rabbit ear artery. Br J Plast Surg1991; 44: 341–347.
GherardiniGSamuelsonUJernbeckJ, et al.Comparison of vascular effects of ropivacaine and lidocaine on isolated rings of human arteries. Acta Anaesthesiol Scand1995; 39: 765–768.
57.
NakamuraKTodaHKakuyamaM, et al.Direct vascular effect of ropivacaine in femoral artery and vein of the dog. Acta Anaesthesiol Scand1993; 37: 269–273.
58.
ApsCReynoldsF. The effect of concentration on vasoactivity of bupivacaine and lignocaine. Br J Anaesth1976; 48: 1171–1174.
59.
JohanssonSEAbdolalizadehBSheykhzadeM, et al.Vascular pathology of large cerebral arteries in experimental subarachnoid hemorrhage: vasoconstriction, functional CGRP depletion and maintained CGRP sensitivity. Eur J Pharmacol2019; 846: 109–118. 20190114.
60.
MasoodTLakatosSKisG, et al.Subarachnoid hemorrhage depletes calcitonin gene-related peptide levels of trigeminal neurons in rat Dura mater. Cells2024; 13: 20240409.
61.
ArandAGZuccarelloMSkidmoreBA, et al.Effect of subarachnoid haemorrhage on trigeminovascular calcitonin-gene-related peptide and substance P of the rat dura mater versus cerebral vasculature. Acta Neurochir (Wien)1994; 127: 103–111.
62.
KinoshitaHAzmaTNakahataK, et al.Inhibitory effect of high concentration of glucose on relaxations to activation of ATP-sensitive K+ channels in human omental artery. Arterioscler, Thromb, Vasc Biol2004; 24: 2290–2295.
63.
QureshiAIPfeifferKBabarS, et al.Intra-arterial injection of lidocaine into middle meningeal artery to treat intractable headaches and severe migraine. J Neuroimaging2021; 31: 1126–1134. 20210813.
64.
ZhanSLiYWangG, et al.Effectiveness of intra-arterial anesthesia for uterine fibroid embolization using dilute lidocaine. Eur Radiol2005; 15: 1752–1756. 20050205.
65.
LeeSHHahnSTParkSH.Intraarterial lidocaine administration for relief of pain resulting from transarterial chemoembolization of hepatocellular carcinoma: its effectiveness and optimal timing of administration. Cardiovasc Intervent Radiol2001; 24: 368–371. 20011108.
66.
WoolfCJ.Central sensitization: implications for the diagnosis and treatment of pain. Pain2011; 152: S2–s15. 20101018.
67.
KuoCPJaoSWChenKM, et al.Comparison of the effects of thoracic epidural analgesia and i.v. infusion with lidocaine on cytokine response, postoperative pain and bowel function in patients undergoing colonic surgery. Br J Anaesth2006; 97: 640–646. 20060904.
68.
HollmannMWDurieuxME. Local anesthetics and the inflammatory response: a new therapeutic indication?Anesthesiology2000; 93: 858–875.
69.
MacGregorRRThornerREWrightDM. Lidocaine inhibits granulocyte adherence and prevents granulocyte delivery to inflammatory sites. Blood1980; 56: 203–209.
70.
CiccozziMMengaRRicciG, et al.Critical review of sham surgery clinical trials: confounding factors analysis. Ann Med Surg (Lond)2016; 12: 21–26. 2016/11/23.
71.
FahnS. The place of placebos/sham surgery in clinical trials. Arch Neurol2002; 59: 325–326.
72.
WolfBRBuckwalterJA. Randomized surgical trials and “sham” surgery: relevance to modern orthopaedics and minimally invasive surgery. Iowa Orthop J2006; 26: 107–111. 2006/06/23.
73.
DhakalLPHodgeDONagelJ, et al.Safety and tolerability of gabapentin for aneurysmal subarachnoid hemorrhage (sah) headache and meningismus. Neurocrit Care2015; 22: 414–421.
74.
HileGBCookAM. Treatment of headache in aneurysmal subarachnoid hemorrhage: multimodal approach. Interdisciplinary Neurosurgery2020; 22: 100857.
75.
WilliamsKAHardenN.Managing the placebo effect: enhancing the signal-to-noise ratio. Curr Pain Headache Rep2011; 15: 35–38. 2010/12/15.
76.
VickersAJde CraenAJ.Why use placebos in clinical trials? A narrative review of the methodological literature. J Clin Epidemiol2000; 53: 157–161. 2000/03/24.
77.
JensenKTfelt-HansenPHansenEW, et al.Introduction of a novel self-injector for sumatriptan. A controlled clinical trial in general practice. Cephalalgia1995; 15: 423–429. 1995/10/01.
78.
AutretAValadeDDebiaisS.Placebo and other psychological interactions in headache treatment. J Headache Pain2012; 13: 191–198. 2012/03/01.
79.
EdwardsRJBritzGWMarshH. Chronic headaches due to occult hydrocephalus. J R Soc Med2003; 96: 77–78.
80.
LiaoCYLiCCLiuHY, et al.Migraine headaches after major surgery with general or neuraxial anesthesia: a nationwide propensity-score matched study. Int J Environ Res Public Health2021; 19: 20211230.
81.
Havanka-KanniainenHHokkanenEMyllyläVV. Efficacy of nimodipine in the prophylaxis of migraine. Cephalalgia1985; 5: 39–43.
82.
LuSRLiaoYCFuhJL, et al.Nimodipine for treatment of primary thunderclap headache. Neurology2004; 62: 1414–1416.
AssarzadeganFAsadollahiMHesamiO, et al.Secondary headaches attributed to arterial hypertension. Iran J Neurol2013; 12: 106–110.
85.
SalgadoFDouangpraseuthSDickersonJR, et al.Lidocaine infusion for the treatment of headache associated with subarachnoid hemorrhage: a case report. A A Pract2022; 16: e01576. 20220323.
86.
DienerHCTassorelliCDodickDW, et al.Guidelines of the international headache society for controlled trials of acute treatment of migraine attacks in adults: fourth edition. Cephalalgia2019; 39: 687–710. 2019/02/27.
87.
HjermstadMJFayersPMHaugenDF, et al.Studies comparing numerical rating scales, verbal rating scales, and visual analogue scales for assessment of pain intensity in adults: a systematic literature review. J Pain Symptom Manage2011; 41: 1073–1093. 2011/05/31.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
